Zacks Research Cuts Earnings Estimates for Core Laboratories

Core Laboratories Inc. (NYSE:CLB) – Research analysts at Zacks Research reduced their FY2026 EPS estimates for shares of Core Laboratories in a report issued on Monday, September 14th. Zacks Research analyst Team now forecasts that the oil and gas company will post earnings of $0.61 per share for the year, down from their previous estimate of $0.62. The consensus estimate for Core Laboratories’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories’ Q3 2027 earnings at $0.18 EPS, Q4 2027 earnings at $0.22 EPS, FY2027 earnings at $0.78 EPS, Q1 2028 earnings at $0.12 EPS and Q2 2028 earnings at $0.39 EPS.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The business had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. During the same period last year, the firm posted $0.19 earnings per share. The company’s revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

CLB has been the topic of several other reports. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Thursday, August 13th. Weiss Ratings upgraded Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Finally, Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Core Laboratories Stock Performance

NYSE CLB opened at $12.25 on Wednesday. The stock’s 50 day simple moving average is $11.83 and its 200-day simple moving average is $13.68. Core Laboratories has a 1-year low of $9.79 and a 1-year high of $20.36. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. The company has a market cap of $562.09 million, a PE ratio of 21.87, a price-to-earnings-growth ratio of 2.42 and a beta of 1.08.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Monday, August 10th were issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, August 10th. Core Laboratories’s dividend payout ratio (DPR) is 7.14%.

Insider Buying and Selling at Core Laboratories

In other Core Laboratories news, CEO Lawrence Bruno acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the acquisition, the chief executive officer owned 262,438 shares of the company’s stock, valued at approximately $2,829,081.64. This trade represents a 1.94% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC grew its holdings in Core Laboratories by 13.6% during the 2nd quarter. Tidal Investments LLC now owns 80,853 shares of the oil and gas company’s stock worth $942,000 after acquiring an additional 9,652 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Core Laboratories during the second quarter worth about $555,000. Amundi increased its position in Core Laboratories by 63.4% during the second quarter. Amundi now owns 52,065 shares of the oil and gas company’s stock worth $607,000 after buying an additional 20,208 shares during the period. AXQ Capital LP acquired a new stake in shares of Core Laboratories in the second quarter valued at approximately $225,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Core Laboratories in the second quarter valued at approximately $288,000. 97.81% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Core Laboratories

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $0.78 from $0.77, lifted Q3 2027 EPS to $0.18 from $0.16, and increased Q1 2028 EPS to $0.12 from $0.11. The firm also raised Q2 2028 EPS to $0.39 from $0.31 and FY2028 EPS to $1.11 from $1.10, providing a favorable longer-term earnings outlook. Core Laboratories analyst estimate revisions
• Neutral Sentiment: The revisions leave Zacks’ current full-year consensus estimate at $0.56 EPS, while the company’s latest quarter showed EPS of $0.11, above expectations, but revenue declined 4.3% year over year to $124.61 million. Core Laboratories has guided to Q3 2026 EPS of $0.12-$0.20.
• Negative Sentiment: Zacks lowered its FY2026 EPS forecast to $0.61 from $0.62, reduced Q3 2026 EPS to $0.17 from $0.18, and cut Q4 2027 EPS to $0.22 from $0.24. These reductions point to some near-term earnings pressure and temper the impact of the longer-term upgrades. Core Laboratories earnings estimates

About Core Laboratories

Core Laboratories N.V. (NYSE: CLB) is a global provider of reservoir description and production enhancement services for the oil and natural gas industry. The company helps exploration and production companies evaluate subsurface formations, characterize reservoirs and improve the recovery of hydrocarbons from existing fields.

Core Laboratories’ reservoir description activities include laboratory analysis of rock and fluid samples, core analysis, special core analysis, fluid and pressure-volume-temperature studies, geochemical services and related geological and petrophysical evaluations.